DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Feasibility of transdermal delivery of prochlorperazine.

Author(s): Obata Y, Otake Y, Takayama K

Affiliation(s): Department of Pharmaceutics, Hoshi University, Tokyo, Japan. obata@hoshi.ac.jp

Publication date & source: 2010, Biol Pharm Bull., 33(8):1454-7.

Publication type: In Vitro; Research Support, Non-U.S. Gov't

Prochlorperazine (PCPZ) is used as a drug of first choice to treat opioid-induced nausea and vomiting. To examine the feasibility of the development of a transdermal drug delivery system for PCPZ, we performed an in vitro skin permeation study with hairless mouse skin. When the concentration of L-menthol in the hydrogel was 0-0.5%, the PCPZ flux was small; on the other hand, the flux was increased remarkably when the L-menthol concentration was higher than 1%. The optimal formulation of hydrogel would be contained 20% isopropanol (IPA), 10% N-methyl-2-pyrrolidone (NMP), 2% L-menthol and 1% PCPZ. The strong inhibitory effects to stereotyped behavior were observed at 4 h after administration of PCPZ hydrogel, and the efficacy was sustained for at least 8 h after the administration in mice in vivo. Thus, it was considered that PCPZ was delivered to brain via systemic circulation by the administration of PCPZ hydrogel.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017